ArticleBMC oral health2025
Desmoglein-3 autoantibodies in tissues of oral lichen planus patients and its correlation with disease severity: case-control study.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06652477 (Evaluation of Desmoglein-3 Autoantibodies in the Tissues of Atrophic/Bullous Erosive Oral Lichen Planus and Correlation with Disease Severity), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Desmoglein-3 Autoantibodies in the Tissues of Atrophic/Bullous Erosive Oral Lichen Planus and Correlation with Disease Severity
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to the not fully understood exact pathogenesis of oral lichen planus, the patients receive symptomatic management, rather than a curative treatment. Consequently, revealing the pathogenesis of OLP is a primary concern in oral medicine research. Elevated levels of circulating antibodies against Desmoglein 3 have been discovered in the serum of OLP patients. The aim of the present study was to evaluate the level of Desmoglein 3 autoantibodies in tissue biopsies of atrophic/bullous erosive OLP and to correlate it with the disease severity, in attempt to reveal if it has a role in the pathogenesis of the disease.
methodsThis is a case-control study, tissue biopsies were obtained from clinically and histopathologically diagnosed atrophic/bullous-erosive oral lichen planus (OLP) lesions (n = 10). The oral lichen planus biopsies were compared with healthy uninflamed gingival tissues excised during periodontal surgeries (n = 10). The tissue biopsies were tested for quantitative levels of desmoglein 3 autoantibodies using ELISA test. The clinical severity of oral lichen planus lesions was evaluated by Elsabagh scoring system. The levels of desmoglein 3 autoantibodies were correlated with the disease severity.
resultsThe concentration of desmoglein 3 autoantibodies level in tissues of patients with atrophic/erosive OLP [3395.4 (± 526.9) Pg/g] was significantly higher (p < 0.001) than in tissues of healthy controls [2329.7 (± 307.6) Pg/g]. The student's t-test was used to compare between the two groups. Moreover, the concentration of desmoglein 3 autoantibodies showed a statistically significant positive correlation (ρ = 0.801) with OLP clinical severity scores (p = 0.005).
conclusionsDesmoglein 3 autoantibodies were detected in higher concentrations in oral lichen planus tissues compared to healthy controls. Increased concentration of desmoglein 3 autoantibodies is correlated with an increase in oral lichen planus clinical severity scores and vice versa. So, further investigation is needed to discover the exact role of Dsg3 autoantibodies in the pathogenesis of OLP.
trial registrationThe study was registered on the Clinical Trial Registration Site (registration code: NCT06652477, last updated on 22-10-2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.